MA27095A1 - Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer - Google Patents
Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancerInfo
- Publication number
- MA27095A1 MA27095A1 MA27730A MA27730A MA27095A1 MA 27095 A1 MA27095 A1 MA 27095A1 MA 27730 A MA27730 A MA 27730A MA 27730 A MA27730 A MA 27730A MA 27095 A1 MA27095 A1 MA 27095A1
- Authority
- MA
- Morocco
- Prior art keywords
- quinazoline
- phenylamino
- yloxy
- acetamide
- allyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 12 décembre 2001 60/340,885 Voir en annexe le titre de l'invention et le texte de l'abrégé Formes de sels de E-2-méthoxy-N-(3-(4-(3-méthyl-pyridine-3-yloxy)-phénylamino)-quinazoline-6-yl)-allyl)-acétamide, leur préparation et leur utilisation contre le cancer La présente invention concerne les sels succinate et malonate de E-2-méthoxy-N-(3-{4- [3-méthyl-4- (6-méthylpyridine-3-yloxy) -phénylamino] -quinazoline-6-yl}-allyl) -acétamide répondant à la formule (I): Plus particulièrement, la présente invention concerne les sels sesquisuccinate et di-malonate du composé de formule (I). La présente invention concerne également des compositions pharmaceutiques contenant les sels succinate et malonate du composé de formule (I). La présente invention concerne en outre des méthodes pour le traitement de maladies hyperproliferatives, telles que des cancers, chez des mammifères, notamment chez l'homme, par administration des sels précités, et des procédés pour la préparation des sels précités.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34088501P | 2001-12-12 | 2001-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27095A1 true MA27095A1 (fr) | 2004-12-20 |
Family
ID=23335337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27730A MA27095A1 (fr) | 2001-12-12 | 2004-06-08 | Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6844349B2 (fr) |
| EP (1) | EP1456199A1 (fr) |
| JP (1) | JP4202926B2 (fr) |
| KR (1) | KR20040065259A (fr) |
| CN (1) | CN1608062A (fr) |
| AP (1) | AP2004003059A0 (fr) |
| AR (1) | AR037772A1 (fr) |
| AU (1) | AU2002366581A1 (fr) |
| BR (1) | BR0214876A (fr) |
| CA (1) | CA2469889A1 (fr) |
| DO (1) | DOP2002000544A (fr) |
| EA (1) | EA007412B1 (fr) |
| EC (1) | ECSP045148A (fr) |
| GE (1) | GEP20063872B (fr) |
| GT (1) | GT200200272A (fr) |
| HR (1) | HRP20040530A2 (fr) |
| HU (1) | HUP0402662A2 (fr) |
| IL (1) | IL161915A0 (fr) |
| IS (1) | IS7227A (fr) |
| MA (1) | MA27095A1 (fr) |
| MX (1) | MXPA04005678A (fr) |
| NO (1) | NO20042925L (fr) |
| NZ (1) | NZ532436A (fr) |
| OA (1) | OA12735A (fr) |
| PA (1) | PA8561401A1 (fr) |
| PE (1) | PE20030716A1 (fr) |
| PL (1) | PL370858A1 (fr) |
| RS (1) | RS46404A (fr) |
| TN (1) | TNSN04112A1 (fr) |
| TW (1) | TW200301103A (fr) |
| UA (1) | UA75482C2 (fr) |
| UY (1) | UY27572A1 (fr) |
| WO (1) | WO2003050108A1 (fr) |
| ZA (1) | ZA200402995B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4181502B2 (ja) * | 2001-12-12 | 2008-11-19 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療するためのキナゾリン誘導体 |
| EP2280003B1 (fr) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Procédé pour la préparation de modulateurs de kinases de type récepteur |
| KR20050085749A (ko) * | 2002-12-18 | 2005-08-29 | 화이자 프로덕츠 인크. | 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체 |
| JP2006512355A (ja) * | 2002-12-19 | 2006-04-13 | ファイザー・プロダクツ・インク | Ｅ−２−メトキシ−ｎ−（３−｛４−［３−メチル−４−（６−メチルピリジン−３−イルオキシ）−フェニルアミノ］−キナゾリン−６−イル｝−アリル）−アセトアミドの複合体、それらの製造方法および使用 |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| MXPA06001989A (es) * | 2003-08-18 | 2006-05-17 | Pfizer Prod Inc | Programa de dosificacion para un nuevo agente anticanceroso. |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| AU2004287416C1 (en) * | 2003-10-27 | 2010-09-09 | Merck Sharp & Dohme Corp. | CCR-2 antagonist salt |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| WO2005121124A1 (fr) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Complexes de e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide et procedes de preparation de ces derniers |
| US8318701B2 (en) | 2004-07-27 | 2012-11-27 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
| US20080194596A1 (en) * | 2005-06-03 | 2008-08-14 | Frizer Inc. | Therapeutic Combination Including a Selective Erbb2 Inhibitor |
| CA2610491A1 (fr) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Derives bicycliques pour le traitement de croissance cellulaire anormale |
| NZ572368A (en) * | 2006-05-16 | 2011-04-29 | Gilead Sciences Inc | Method and compositions for treating hematological malignancies |
| US20100004238A1 (en) | 2006-12-12 | 2010-01-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| ES2360014T3 (es) * | 2006-12-21 | 2011-05-31 | Pfizer Products Inc. | Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina. |
| NZ580868A (en) * | 2007-04-10 | 2011-07-29 | Myriad Pharmaceuticals Inc | Dosages and methods for the treatment of cancer |
| UY31704A (es) | 2008-03-12 | 2009-11-10 | Takeda Pharmaceutical | Compuesto heterociclico fusionado |
| EA018308B1 (ru) * | 2008-07-08 | 2013-07-30 | Джилид Сайэнс, Инк. | Соли соединений ингибиторов вич |
| EP2387563B2 (fr) | 2009-01-16 | 2022-04-27 | Exelixis, Inc. | Sel de malate de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011153050A1 (fr) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Méthodes et utilisation de composés qui se lient au complexe du récepteur her2/neu |
| WO2011153049A1 (fr) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Procédés et utilisation de composés se liant au complexe récepteur her2/neu |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| EP3317323B1 (fr) | 2015-07-01 | 2021-05-26 | California Institute of Technology | Systèmes d'administration à base de polymère d'acide mucique cationique |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| JP7483193B2 (ja) | 2018-06-13 | 2024-05-15 | カリフォルニア・インスティテュート・オブ・テクノロジー | 血脳バリアを越えるためのナノ粒子とそれを用いた治療法 |
| WO2022009815A1 (fr) * | 2020-07-06 | 2022-01-13 | キッセイ薬品工業株式会社 | Succinate de composé octahydrothiénoquinoline et cristaux de celui-ci |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884418B1 (en) * | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0912559B1 (fr) * | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase |
| WO2001098277A2 (fr) * | 2000-06-22 | 2001-12-27 | Pfizer Products Inc. | Derives bicycliques substitues destines au traitement de la croissance cellulaire anormale |
-
2002
- 2002-11-11 EP EP02804543A patent/EP1456199A1/fr not_active Withdrawn
- 2002-11-11 RS YU46404A patent/RS46404A/sr unknown
- 2002-11-11 GE GE5562A patent/GEP20063872B/en unknown
- 2002-11-11 KR KR10-2004-7009073A patent/KR20040065259A/ko not_active Ceased
- 2002-11-11 WO PCT/IB2002/004708 patent/WO2003050108A1/fr not_active Ceased
- 2002-11-11 CA CA002469889A patent/CA2469889A1/fr not_active Abandoned
- 2002-11-11 OA OA1200400161A patent/OA12735A/en unknown
- 2002-11-11 BR BR0214876-5A patent/BR0214876A/pt not_active IP Right Cessation
- 2002-11-11 JP JP2003551132A patent/JP4202926B2/ja not_active Expired - Fee Related
- 2002-11-11 HR HR20040530A patent/HRP20040530A2/hr not_active Application Discontinuation
- 2002-11-11 PL PL02370858A patent/PL370858A1/xx not_active Application Discontinuation
- 2002-11-11 AP APAP/P/2004/003059A patent/AP2004003059A0/en unknown
- 2002-11-11 MX MXPA04005678A patent/MXPA04005678A/es active IP Right Grant
- 2002-11-11 HU HU0402662A patent/HUP0402662A2/hu unknown
- 2002-11-11 AU AU2002366581A patent/AU2002366581A1/en not_active Abandoned
- 2002-11-11 NZ NZ532436A patent/NZ532436A/en unknown
- 2002-11-11 EA EA200400674A patent/EA007412B1/ru not_active IP Right Cessation
- 2002-11-11 UA UA20040604566A patent/UA75482C2/uk unknown
- 2002-11-11 CN CNA028248554A patent/CN1608062A/zh active Pending
- 2002-11-11 IL IL16191502A patent/IL161915A0/xx unknown
- 2002-12-06 TW TW091135465A patent/TW200301103A/zh unknown
- 2002-12-09 UY UY27572A patent/UY27572A1/es not_active Application Discontinuation
- 2002-12-10 US US10/315,862 patent/US6844349B2/en not_active Expired - Fee Related
- 2002-12-10 PE PE2002001185A patent/PE20030716A1/es not_active Application Discontinuation
- 2002-12-10 DO DO2002000544A patent/DOP2002000544A/es unknown
- 2002-12-10 AR ARP020104779A patent/AR037772A1/es unknown
- 2002-12-12 PA PA20028561401A patent/PA8561401A1/es unknown
- 2002-12-12 GT GT200200272A patent/GT200200272A/es unknown
-
2004
- 2004-04-19 IS IS7227A patent/IS7227A/is unknown
- 2004-04-20 ZA ZA200402995A patent/ZA200402995B/en unknown
- 2004-06-08 MA MA27730A patent/MA27095A1/fr unknown
- 2004-06-11 TN TNP2004000112A patent/TNSN04112A1/fr unknown
- 2004-06-11 EC EC2004005148A patent/ECSP045148A/es unknown
- 2004-07-09 NO NO20042925A patent/NO20042925L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27095A1 (fr) | Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer | |
| MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
| MA27311A1 (fr) | Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs | |
| MA26688A1 (fr) | 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26861A1 (fr) | Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| TR200103186T2 (tr) | MEK enzimlerinin inhibitörleri olarak kinolin türevleri | |
| MA27174A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4. | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| EE200200207A (et) | Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid | |
| BR0107147A (pt) | Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações | |
| BR9711135A (pt) | Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| AU2002218167A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
| MA29213B1 (fr) | Quinolones a substitution macrolones - amino | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| AU2003228674A1 (en) | Muscarinic antagonists | |
| PT828728E (pt) | Di-hidrobenzofuranos de fenilo | |
| DE60206198T2 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| AU3563695A (en) | Novel piperidine derivatives with paf antagonist activity | |
| AU1185801A (en) | Novel compounds | |
| MA27661A1 (fr) | Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant |